呼吸治疗市场规模、份额、成长分析（按药物类别、疾病类型、给药途径、分销管道、地区、产业预测，2025-2032 年）

预计 2023 年全球呼吸药物市场价值将达到 37 亿美元，并从 2024 年的 40.1 亿美元增长到 2032 年的 77.1 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.5%。

受全球呼吸系统疾病激增的推动，预计2025年至2032年间，呼吸系统药物市场将大幅成长。由于空气污染加剧、过敏原暴露增加以及人们对呼吸系统疾病认识的提高等因素，诊断和治疗率正在上升。在高所得国家，超过70%的慢性阻塞性肺病（COPD）病例与吸烟有关，而在中低收入国家，这一比例为30%至40%，家庭空气污染也扮演关键角色。吸烟仍然是导致COPD、肺癌和呼吸道感染疾病等呼吸系统疾病的主要原因，因为它会长期损害肺功能。这凸显了对有效呼吸系统药物治疗这些常见疾病的迫切需求。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

呼吸系统药物市场规模（按药物类别和复合年增长率） (2025-2032)

• 市场概览
• 短效β-2激动剂（SABA）
• 长效β-2激动剂（LABA）
• 吸入性皮质类固醇（ICS）
• 抗胆碱药物
• 抗组织胺药
• 血管扩张剂
• 伴随用药
• 其他的

呼吸药物市场规模（依疾病类型及复合年增长率）（2025-2032）

• 市场概览
• 气喘
• 慢性支气管炎
• 慢性阻塞性肺病（COPD）
• 胸腔积水
• 其他的

呼吸药物市场规模（依给药途径及复合年增长率）（2025-2032）

• 市场概览
• 吸入
• 肠内
• 肠外

呼吸药物市场规模（依分销管道划分）及复合年增长率（2025-2032）

• 市场概览
• 医院药房
• 零售药局
• 网路药局

呼吸药物市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

    主要企业简介

    • 葛兰素史克公司（GSK）（英国）
    • 阿斯特捷利康公司（英国）
    • 勃林格殷格翰国际有限公司（德国）
    • 默克公司（美国）
    • 诺华公司（瑞士）
    • F. Hoffmann-La Roche Ltd.（瑞士）
    • 梯瓦製药工业股份有限公司（以色列）
    • 赛诺菲（法国）
    • 辉瑞公司（美国）
    • 艾伯维公司（美国）
    • Vertex Pharmaceuticals Incorporated（美国）
    • 迈兰製药公司（美国）
    • 太阳製药工业有限公司（印度）
    • 鲁宾有限公司（印度）
    • 西普拉有限公司（印度）
    • Chiesi Farmaceutici SpA（义大利）
    • 住友大日本製药有限公司（日本）
    • 贝希姆科製药股份有限公司（孟加拉）
    • Respirerx Pharmaceuticals Inc.（美国）
    • Viatris Inc.（美国）

结论和建议

Global Respiratory Drugs Market size was valued at USD 3.7 billion in 2023 and is poised to grow from USD 4.01 billion in 2024 to USD 7.71 billion by 2032, growing at a CAGR of 8.5% during the forecast period (2025-2032).

The respiratory drugs market is poised for significant growth between 2025 and 2032, driven by a surge in respiratory disorders globally. Factors such as rising air pollution, increased allergen exposure, and heightened awareness of respiratory diseases have led to greater diagnosis and treatment rates. In high-income countries, over 70% of Chronic Obstructive Pulmonary Disease (COPD) cases are attributed to tobacco smoking, while in low- and middle-income countries, this figure is 30-40%, with household air pollution also playing a critical role. Smoking remains a leading cause of respiratory issues, including COPD, lung cancer, and respiratory infections, as it inflicts long-term damage on lung function. This underscores the urgent need for effective respiratory therapies to manage these prevalent conditions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Respiratory Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Respiratory Drugs Market Segments Analysis

Global Respiratory Drugs Market is segmented by Drug Class, Disease Type, Route of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Short-Acting Beta2-Agonists (SABA), Long-Acting Beta2-Agonists (LABA), Inhaled Corticosteroids (ICS), Anticholinergics, Antihistamines, Vasodilators, Combination Drugs and Others. Based on Disease Type, the market is segmented into Asthma, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Pleural Effusion and Others. Based on Route of Administration, the market is segmented into Inhalation, Enteral and Parenteral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Respiratory Drugs Market

The Global Respiratory Drugs market is significantly driven by advancements in artificial intelligence, which are transforming the discovery process of new respiratory medications. By swiftly analyzing extensive datasets, AI technologies can pinpoint potential compounds and biological targets with remarkable speed and efficiency. Machine learning algorithms can effectively simulate the interactions between drug candidates and human biology, thereby streamlining the preclinical phase and accelerating overall development timelines. Notably, AI platforms such as BenevolentAI and Atomwise are being harnessed to create groundbreaking therapies for conditions like asthma and chronic obstructive pulmonary disease (COPD), empowering pharmaceutical companies to enhance innovation while minimizing research and development costs.

Restraints in the Global Respiratory Drugs Market

The Global Respiratory Drugs market faces certain constraints, particularly in the integration of artificial intelligence into drug development. This process demands a significant investment in computational infrastructure, skilled workforce, and ongoing software enhancements, which can be financially burdensome for smaller pharmaceutical firms or those operating in developing regions. Additionally, the challenge of incorporating AI tools into existing legacy systems often results in technical and logistical difficulties, hindering the progress of digital transformation within research and development efforts for respiratory medications. These factors collectively pose considerable obstacles to the advancement and efficiency of respiratory drug innovation in the market.

Market Trends of the Global Respiratory Drugs Market

The Global Respiratory Drugs market is increasingly influenced by the rise of AI-enabled smart inhalers, which are transforming respiratory care. These innovative devices, such as Propeller Health's inhaler sensors, track medication adherence, monitor symptoms, and offer real-time feedback to both patients and healthcare providers. By ensuring proper inhaler techniques and minimizing missed doses, these technologies enhance patient engagement and adherence to treatment protocols. Furthermore, the data generated facilitates personalized treatment plans, thereby improving clinical outcomes. As advancements in AI and digital health technology progress, the integration of smart inhalers is expected to drive substantial growth in the respiratory drugs sector, meeting the rising demand for more effective, personalized healthcare solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Respiratory Drugs Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Short-Acting Beta2-Agonists (SABA)
• Long-Acting Beta2-Agonists (LABA)
• Inhaled Corticosteroids (ICS)
• Anticholinergics
• Antihistamines
• Vasodilators
• Combination Drugs
• Others

Global Respiratory Drugs Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Asthma
• Chronic Bronchitis
• Chronic Obstructive Pulmonary Disease (COPD)
• Pleural Effusion
• Others

Global Respiratory Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Inhalation
• Enteral
• Parenteral

Global Respiratory Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Respiratory Drugs Market Size & CAGR (2025-2032)

• North America (Drug Class, Disease Type, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Disease Type, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Disease Type, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Disease Type, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Disease Type, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GlaxoSmithKline Plc (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chiesi Farmaceutici S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beximco Pharmaceuticals Ltd. (Bangladesh)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Respirerx Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations